Evotec SE (EVO) Amortization - Intangibles (2009 - 2023)

Evotec SE (EVO) reported Amortization - Intangibles of -$5520.6 for Q4 2023, down 571.19% sequentially from -$822.52 in Q2 2021.

Evotec SE (EVO) Amortization - Intangibles (2009 - 2023) Analysis & Trends

Evotec SE (EVO) has 3 years of Amortization - Intangibles data on file, last reported at -$5520.6 in Q4 2023.

For the quarter ending Q4 2023, Amortization - Intangibles changed N/A year-over-year to -$5520.6; the trailing twelve-month figure through Dec 2023 stood at $26.8 million (changed N/A YoY), and the FY2023 full-year result was -$5520.6, changed N/A from the prior year.
Amortization - Intangibles eased to -$5520.6 in Q4 2023, from -$822.52 in the prior quarter.
In the past five years, Amortization - Intangibles ranged from a high of -$822.52 in Q2 2021 to a low of -$5520.6 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Evotec SE	351.60 Mn	351.08 Mn	-

Download Data